Risankizumab(一种IL-23抑制剂)治疗强直性脊柱炎:一项随机、双盲、安慰剂对照、概念验证、剂量探索的2期研究结果
这项随机双盲安慰剂对照2期研究纳入159例生物制剂初治的活动性强直性脊柱炎患者,按1:1:1:1随机接受Risankizumab 18 mg单次、90 mg或180 mg(第1天及第8、16、24周)或安慰剂治疗24周。第12周ASAS40应答率在18 mg、90 mg、180 mg组分别为25.5%、20.5%、15.0%,安慰剂组为17.5%;180 mg组与安慰剂组估计差值-2.5%(95%CI -21.8至17.0;p=0.42),未达主要终点。结论认为Risankizumab未达主要终点,与安慰剂相比无临床意义改善的证据。
要点
- 180 mg组与安慰剂组第12周ASAS40应答率估计差值-2.5%(95%CI -21.8至17.0;p=0.42),未达主要终点。
- 18 mg、90 mg、180 mg组第12周ASAS40应答率分别为25.5%、20.5%、15.0%,安慰剂组17.5%。
- 各治疗组不良事件发生率相似。
核心结论
- Risankizumab治疗未能达到研究主要终点,与安慰剂相比在活动性强直性脊柱炎患者中无临床意义改善的证据,提示IL-23可能并非强直性脊柱炎疾病发病和症状的相关驱动因素。
研究设计与样本
- 随机、双盲、安慰剂对照、概念验证、剂量探索的2期研究,纳入159例生物制剂初治的活动性强直性脊柱炎患者(Bath强直性脊柱炎疾病活动指数评分≥4)。
- 患者按1:1:1:1随机接受Risankizumab 18 mg单次剂量、90 mg或180 mg(第1天及第8、16、24周)或安慰剂,双盲期24周。
- 主要结局为第12周ASAS40应答(强直性脊柱炎国际评估工作组40%改善);安全性在至少接受一剂研究药物的患者中评估。
主要发现
- 第12周ASAS40应答率在18 mg组为25.5%、90 mg组为20.5%、180 mg组为15.0%,安慰剂组为17.5%。
- 180 mg Risankizumab组与安慰剂组之间应答比例的估计差值为-2.5%(95%CI -21.8至17.0;p=0.42)。
- 各治疗组不良事件发生率相似。
关键数值与推荐
- 主要终点为第12周ASAS40应答;180 mg组与安慰剂组的估计差值-2.5%(95%CI -21.8至17.0;p=0.42),未达主要终点。
- 第12周ASAS40应答率:18 mg组25.5%、90 mg组20.5%、180 mg组15.0%、安慰剂组17.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS). METHODS: A total of 159 patients with biological-naïve AS, with active disease (Bath Ankylosing Spondylitis Disease Activity Index score of ≥4), were randomised (1:1:1:1) to risankizumab (18 mg single dose, 90 mg or 180 mg at day 1 and weeks 8, 16 and 24) or placebo over a 24-week blinded period. The primary outcome was a 40% improvement in Assessment in Spondylo Arthritis International Society (ASAS40) at week 12. Safety was assessed in patients who received at least one dose of study drug. RESULTS: At week 12, ASAS40 response rates were 25.5%, 20.5% and 15.0% in the 18 mg, 90 mg and 180 mg risankizumab groups, respectively, compared with 17.5% in the placebo group. The estimated difference in proportion between the 180 mg risankizumab and placebo groups (primary endpoint) was -2.5% (95% CI -21.8 to 17.0; p=0.42). Rates of adverse events were similar in all treatment groups. CONCLUSIONS: Treatment with risankizumab did not meet the study primary endpoint and showed no evidence of clinically meaningful improvements compared with placebo in patients with active AS, suggesting that IL-23 may not be a relevant driver of disease pathogenesis and symptoms in AS. TRIAL REGISTRATION NUMBER: NCT02047110; Pre-results.
引用
- Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018. PMID: 29945918. doi:10.1136/annrheumdis-2018-213328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。